Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Wayne Vacarro, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists
John Lloyd, Heather J Finlay, Karnail Atwal, et al.
Cancer Science
|
September 2, 2022
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
Masaki Ri, Kenshi Suzuki, Tadao Ishida, et al.
Science Advances
|
April 5, 2023
Revealing the key role of molecular packing on interface spin polarization at two-dimensional limit in spintronic devices
Zhongzhong Luo, Xiangxiang Song, Xiaolong Liu, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 25, 2015
Pseudosaccharin amines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Alexander Kover, et al.
ACS Applied Materials & Interfaces
|
October 8, 2019
Targeted Surface Doping with Reversible Local Environment Improves Oxygen Stability at the Electrochemical Interfaces of Nickel-Rich Cathode Materials
James D Steiner, Hao Cheng, Julia Walsh, et al.
Journal of Medicinal Chemistry
|
March 14, 2012
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor
Heather J Finlay, John Lloyd, Wayne Vaccaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
Discovery of a potent and novel motilin agonist
James J Li, Hann-Guang Chao, Haixia Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Bioorganic & Medicinal Chemistry Letters
|
January 26, 2010
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Wayne Vacarro, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists
John Lloyd, Heather J Finlay, Karnail Atwal, et al.
Cancer Science
|
September 2, 2022
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
Masaki Ri, Kenshi Suzuki, Tadao Ishida, et al.
Science Advances
|
April 5, 2023
Revealing the key role of molecular packing on interface spin polarization at two-dimensional limit in spintronic devices
Zhongzhong Luo, Xiangxiang Song, Xiaolong Liu, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 25, 2015
Pseudosaccharin amines as potent and selective KV1.5 blockers
John Lloyd, Heather J Finlay, Alexander Kover, et al.
ACS Applied Materials & Interfaces
|
October 8, 2019
Targeted Surface Doping with Reversible Local Environment Improves Oxygen Stability at the Electrochemical Interfaces of Nickel-Rich Cathode Materials
James D Steiner, Hao Cheng, Julia Walsh, et al.
Journal of Medicinal Chemistry
|
March 14, 2012
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor
Heather J Finlay, John Lloyd, Wayne Vaccaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
Discovery of a potent and novel motilin agonist
James J Li, Hann-Guang Chao, Haixia Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Page
of 6